Observe Medical Asa · OSL:OBSRV
Observe Medical Asa — Investor Presentation (June 2025)
28 slides from Observe Medical Asa's investor presentation, Jun 11, 2025
Slide 1: Company Presentation June 2025
Company Presentation June 2025
Slide 2: Disclaimer (1/2)
Disclaimer (1/2) THIS PRESENTATION IS NOT FOR PUBLICATION NOR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA OR THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATED AND THE DISTRICT OF COLUMBIA) OR ANY OTHER JURISDICTIO
Slide 3: Disclaimer (2/2)
Disclaimer (2/2) This Presentation is intended to present background information on the Company and its business and is not intended to provide complete disclosure upon which an investment decision could be made. Should the Company choose to pursue an offering of its securities in Norway or elsewher
Slide 4: Strategic Vision
STRATEGIC VISION
Slide 5: Strategic Vision: Nordic Medtech Platform
Strategic Vision: Nordic Medtech Platform Scalable and profitable growth, product development, regulatory performance and effective manufacturing Proprietary Platform for innovative “M&A products Nordic ecosystem Opportunities” Start-ups with limited access to Commercialisation and portfolio commerc
Slide 6: Commercial Strategy – Progress and Plans
COMMERCIAL STRATEGY – PROGRESS AND PLANS
Slide 7: Truly transformative years
Truly transformative years 2025 2023 2020-2021 Market Penetration with complete Regulatory integration and Convatec portfolio Focus on launching Commercial launch of UnoMeter • First UnoMeterTM SafetiTM Plus Sippi® in selected 500 and Abdo-Pressure products arriving in January – markets invoicing ac
Slide 8: Observe Medical: Nordic medtech company with global reach
Observe Medical Nordic medtech company with global reach Strong Medtech Portfolio Pocketable Distribution and M&A Urine Output Measurement Ultrasound Opportunities Scalable Platform Manufacturing Product Development Sales & Distribution Quality & Regulatory 8
Slide 9: Market potential – Urine Output measurement systems
Market potential – Urine Output measurement systems Sippi® Current market value for manual systems NOK 1.5 bn ✓ Current global market potential 679 1.548 Market potential OM design 870 Market potential US Design ✓ Sales generated through sales of Based unit and disposable system ✓ Sippi® will give a
Slide 10: Product launch planning 2024-2025
Product launch planning 2024-2025 - taking the position as global leader in Urine Output Measurement Upsell Sippi and Safeti Max to existing Expand portfolio to Recapture the market through UnoMeter family of products clients at higher price points and better allow access to full margins market pote
Slide 11: Product portfolio completed and approved for marketing
Product portfolio completed and approved for marketing Execute on recapturing UnoMeter ’s historical market 2021 annual recurring revenue 2021 annual recurring revenue UnoMeterTM 500 and UnoMeterTM Abdo- UnoMeterTM 500, UnoMeter Safeti Plus and UnoMeterTM PressureTM Abdo-PressureTM Total value: NOK
Slide 12: Marketing collateral completed
Marketing collateral completed Clinical documentation CE-Certificate (MDR), Marketing Collateral Data Sheets & support materials DoC etc. 12
Slide 13: Market penetration process
Market penetration process Product Evaluation Tender Conversion - Delivery of trial order by OM - Approximately 60-80% of the market potential is - OM distributor conducts a product test on managed through public tender contracts 1-3 intensive care units - With contracts lengths of normally 3 years
Slide 14: Order intake of UnoMeter Safeti Plus
Order intake of UnoMeter Safeti Plus 11.3 Latest development: Austria: First repeat order France: First significant repeat order Switzerland: First significant repeat order Portugal: First order Serbia: First order Belgium, Holland, Luxembourg: First repeat order Asia: Tender wins in Thailand and Si
Slide 15: Continued market confirmation after launch of UnoMeter Safeti Plus
Continued market confirmation after launch of UnoMeter Safeti Plus Sales process: 27 • Most common first step is for distributors to place sample orders 16 • The sample orders are used to confirm product quality and drive end-user Repeat orders 41% conversion and tender wins 59% 1st order • Successf
Slide 16: Expected significant next steps
Expected significant next steps • Austria: First significant order of 0,6 mill. NOK expected in the next 1-2 weeks • Switzerland: Second significant order 0,6 mill. NOK expected in the next 2-3 weeks • Jordan: First order 0,5 mill. NOK expected in the next 1-2 weeks • Sweden: Conversion Karolinske U
Slide 17: UnoMeter order intake - 6 months rolling
UnoMeter order intake - 6 months rolling 15.000 14.000 13.000 12.000 11.000 10.000 9.000 8.000 7.000 6.000 5.000 4.000 3.000 2.000 1.000 0 Sep-24 Oct-24 Nov-24 Dec-24 Jan-25 Feb-25 Mar-25 Apr-25 May-25 UnoMeter Safeti Plus UnoMeter 500+ Abdo-Pressure
Slide 18: 85% Geographical coverage and next steps
85% Geographical coverage and next steps • Finalize ongoing market evaluations and tender Orders received from the following countries indicating processes: their share of 2021 Convatec net sales Chile: Austria: Portugal: Holland: • UK Belgium: Poland: Ireland: UAE: • Germany Switzerland: Thailand:
Slide 19: Commercial footprint
Commercial footprint Comments: • Established sales in Europe, South America and Asia • Focus is now on growing market shares in already established markets • Additional geographic expansion into Middle East, South America and AUS/NZ is on the table but second priority 19
Slide 20: The clinical challenge in intensive care
The clinical challenge in intensive care.. 1. Catheter-Associated Urinary Tract Infection (CAUTI) 2. Nursing safety and time optimization 3. Maki DG, Tambyah PA; Engineering out the risk of Infection with Urinary Catheters. Emerging Infectious Diseases: Vol. 7, no. 2, March-April 2001. 4. Marra, A.
Slide 21: Preparations for launch of UnoMeter Safeti MAX
Preparations for launch of UnoMeter Safeti MAX • We have patented technology from Sippi that we expect to be able to provide increased protection towards CAUTI – catheter associated urinary infection. • We can start the production of UnoMeter tomorrow – first 100 sterile units being prepared for pil
Slide 22: Sippi eliminates one of the last manual monitoring procedures in the ICU
Sippi® eliminates one of the last manual monitoring procedures in the ICU Addressing key burdens of current clinical practice, A unique, automated, digital urine meter with wireless representing considerable added value and cost savings data transfer and biofilm control Burdens of current Patient we
Slide 23: Financials
FINANCIALS Keone
Slide 24: Ramp-up from a diversified revenue stream
Ramp-up from a diversified revenue stream Strong revenue outlook in the medium term ✓ Diversified revenue stream going forward from UnoMeter product family, Sippi® and ambition within the distribution business ~400-450m ✓ Gross margin currently under pressure on commoditized products, differentiated
Slide 25: Restructuring our debt
Restructuring our debt ✓ Observe Medical have reached agreements in principle -69 (-66%) with Convatec and Navamedic to reduce their debt position 105 from in total NOK 82 million to NOK 41 million, with an 41 adjusted payment plan for the remaining debt. In addition, Navamedic has agreed a conversi
Slide 26: Summary
SUMMARY Keone
Slide 27: Summary
Summary Products launched Ongoing market penetration Strong pipeline 27
Slide 28: Slide 28